We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
DaVita HealthCare (DVA) Increases Despite Market Slip: Here's What You Need to Know
Read MoreHide Full Article
In the latest market close, DaVita HealthCare (DVA - Free Report) reached $163.16, with a +1% movement compared to the previous day. This move outpaced the S&P 500's daily loss of 0.05%. Meanwhile, the Dow experienced a drop of 0.02%, and the technology-dominated Nasdaq saw an increase of 0.18%.
The kidney dialysis provider's shares have seen a decrease of 0.02% over the last month, surpassing the Medical sector's loss of 4.16% and falling behind the S&P 500's gain of 2.76%.
Investors will be eagerly watching for the performance of DaVita HealthCare in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on October 29, 2024. The company's earnings per share (EPS) are projected to be $2.76, reflecting a 3.16% decrease from the same quarter last year. At the same time, our most recent consensus estimate is projecting a revenue of $3.22 billion, reflecting a 3.23% rise from the equivalent quarter last year.
For the full year, the Zacks Consensus Estimates project earnings of $9.99 per share and a revenue of $12.8 billion, demonstrating changes of +17.95% and +5.43%, respectively, from the preceding year.
Furthermore, it would be beneficial for investors to monitor any recent shifts in analyst projections for DaVita HealthCare. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Therefore, positive revisions in estimates convey analysts' confidence in the company's business performance and profit potential.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. As of now, DaVita HealthCare holds a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that DaVita HealthCare has a Forward P/E ratio of 16.17 right now. This signifies a discount in comparison to the average Forward P/E of 25.02 for its industry.
Also, we should mention that DVA has a PEG ratio of 0.93. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. As the market closed yesterday, the Medical - Outpatient and Home Healthcare industry was having an average PEG ratio of 2.26.
The Medical - Outpatient and Home Healthcare industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 23, positioning it in the top 10% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
DaVita HealthCare (DVA) Increases Despite Market Slip: Here's What You Need to Know
In the latest market close, DaVita HealthCare (DVA - Free Report) reached $163.16, with a +1% movement compared to the previous day. This move outpaced the S&P 500's daily loss of 0.05%. Meanwhile, the Dow experienced a drop of 0.02%, and the technology-dominated Nasdaq saw an increase of 0.18%.
The kidney dialysis provider's shares have seen a decrease of 0.02% over the last month, surpassing the Medical sector's loss of 4.16% and falling behind the S&P 500's gain of 2.76%.
Investors will be eagerly watching for the performance of DaVita HealthCare in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on October 29, 2024. The company's earnings per share (EPS) are projected to be $2.76, reflecting a 3.16% decrease from the same quarter last year. At the same time, our most recent consensus estimate is projecting a revenue of $3.22 billion, reflecting a 3.23% rise from the equivalent quarter last year.
For the full year, the Zacks Consensus Estimates project earnings of $9.99 per share and a revenue of $12.8 billion, demonstrating changes of +17.95% and +5.43%, respectively, from the preceding year.
Furthermore, it would be beneficial for investors to monitor any recent shifts in analyst projections for DaVita HealthCare. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Therefore, positive revisions in estimates convey analysts' confidence in the company's business performance and profit potential.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. As of now, DaVita HealthCare holds a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that DaVita HealthCare has a Forward P/E ratio of 16.17 right now. This signifies a discount in comparison to the average Forward P/E of 25.02 for its industry.
Also, we should mention that DVA has a PEG ratio of 0.93. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. As the market closed yesterday, the Medical - Outpatient and Home Healthcare industry was having an average PEG ratio of 2.26.
The Medical - Outpatient and Home Healthcare industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 23, positioning it in the top 10% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.